Online Exclusives

Online Exclusives

OxyContin Maker Stops Promoting Opioids

Purdue, the manufacturer of OxyContin, cut its sales forces in half and will stop promoting opioids to physicians. Its sales representatives will focus on...

CDC Programs at Risk

Funding for the Centers for Disease Control and Prevention’s (CDC) public health programs have been steadily scaled back by Congress. When the Tax Cuts...

States Consider Importing Drugs From Canada

Lawmakers in more than 34 states are trying to reduce prescription drug costs; some are introducing legislation that would allow drugs to be imported...

FDA Expands Approval of Ferumoxytol Injection for Iron Deficiency Anemia

The U.S. Food and Drug Administration approved a supplemental new drug application for ferumoxytol injection to include all eligible adults with iron deficiency anemia...

Sessions’s Strategy for Tackling Illegal Drug Trade

Attorney General Jeff Sessions, JD, announced that dozens of federal agents and analysts will form a team to disrupt illicit opioid sales online. The...

Protesters Demand More Funding for NHS

Earlier this month, protesters marched through London demanding more government money to support Britain’s overburdened National Health Service (NHS). Trade unions and the main...

E.U. Proposes New Policy for Reviewing Medicines

The European Commission proposed various steps to accelerate the approval of drugs and devices by E.U. member states. The proposed regulation on health-technology assessments...

Three Corporate Giants Team Up to Disrupt Health Care

Amazon, Berkshire Hathaway, and JPMorgan Chase announced that they will form an independent health-care company for their employees in the United States. The companies said...

CDC Director Resigns Over Conflicts of Interest

Brenda Fitzgerald, MD, the director of the Centers for Disease Control and Prevention (CDC), resigned from her appointment over financial conflicts of interest involving...

Higher Drug Prices, Bigger Discounts

According to a recent Wells Fargo analysis, discounts offered last year by drug makers to pharmacy benefit managers averaged more than 40 percent of...
Advertisement

Current Issue

February 2018 Volume 4, Issue 3

This issue features a conversation with National Cancer Institute Director Norman “Ned” Sharpless, MD, a look at the prevalence and controversial nature of academic-industry partnerships, and more.